Citius Pharmaceuticals Inc (CTXR) — Titan Protect Analysis

CTXR

Citius Pharmaceuticals Inc

Healthcare · ·

$0.56

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$16M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-0.73

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-83.6%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$4.00

+614% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 1 analysts covering this stock

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic reli

https://citiuspharma.com

Country: United States Employees: 23 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.763

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0826

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.827

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-81.0%

Historical annualised return based on price data

Max Drawdown

-97.9%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.05

Moves slightly more than the broader market

52W High

$2.48

77% below the year high

52W Low

$0.48

18% above the year low

Avg Volume

828,157

Average daily shares traded — higher means easier to buy and sell

Short Ratio

5.3

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.14

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

1.17

Meaningful debt load — monitor closely

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

80.1%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-1,827.8%

Profit from core operations before interest and tax

Free Cash Flow

$-33,459,172

Negative — the business is spending more than it generates

Revenue (TTM)

$6M

Total revenue over the last 12 months

Net Income

$-46,201,084

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$4.00

Target Median

$4.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go